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Abstract

Polyglutamine (polyQ) stretches exceeding a threshold length confer a toxic function to proteins that
contain them and cause at least nine neurological disorders. The basis for this toxicity threshold is
unclear. Although polyQ expansions render proteins prone to aggregate into inclusion bodies, this may
be a neuronal coping response to more toxic forms of polyQ. The exact structure of these more toxic
forms is unknown. Here we show that the monoclonal antibody 3B5H10 recognizes a species of polyQ
protein in situ that strongly predicts neuronal death. The epitope selectively appears among some of
the many low-molecular-weight conformational states assumed by expanded polyQ and disappears in
higher-molecular-weight aggregated forms, such as inclusion bodies. These results suggest that protein
monomers and possibly small oligomers containing expanded polyQ stretches can adopt a
conformation that is recognized by 3B5H10 and is toxic or closely related to a toxic species.

Misfolding and self-aggregation of specific proteins are a common feature of most common agerelated neurodegenerative diseases, including Huntingtons disease, Alzheimers disease, Parkinsons
disease and amyotrophic lateral sclerosis. In Huntingtons disease, abnormal expansion in the
polyglutamine stretch of the huntingtin protein (Htt) results in protein misfolding and
neurodegeneration, especially in the striatum1. Eight proteins containing polyQ tracts, but otherwise
unrelated to Htt, also result in protein misfolding and neurodegeneration upon polyQ expansion2. For
each of these proteinopathies, an open question is which of the many putative misfolded
conformations and/or aggregated states of the culprit protein is responsible for neurodegeneration.
To determine the species of misfolded proteins that are critical for disease pathogenesis, tools for
detecting species that form naturally in live neurons are needed. Unfortunately, with the exception of
some recently developed antibodies that recognize specific secondary and tertiary protein structures37
, tools to quantify and distinguish among simultaneously existing protein species in situ are generally
lacking.

Even with antibody tools to identify multiple misfolded species in situ, it is difficult to determine the
pathologic importance of any single species within the context of other simultaneously present
species. In clinical research, survival-based statistical techniques such as Cox analysis are routinely used
to determine how each of the multiple simultaneously present putative risk factors relates to an
outcome of interest8,9. Analogously, when multiple species of misfolded protein are simultaneously
present in a neuron, each species can be related to neuronal death by the same survival-based
statistical techniques. For survival analysis to be used, however, the concentrations of multiple protein
species in each of thousands of neurons must be measured, and the survival time for each neuron
must be determined.
In Huntingtons disease, formation of the end-stage, very large aggregated species of mutant Htt
(mHtt), termed an inclusion body, can be a coping response10,11. Inclusion bodies may sequester toxic
species of mHtt, which are distributed diffusely throughout the neuron. However, the species of
diffuse mHtt that leads to neurodegeneration remains elusive.
Here we developed new methods that allowed us to identify and characterize pathogenic species
within the diffuse fraction of mHtt in neurons. First, we used conformation-specific antibodies to
distinguish among species of Htt that exist in situ. Next, we assessed how well each of these species
predicted survival in thousands of neurons by individually tracking the neurons over long periods of
time with an automated microscope10,12. Finally, we applied a modified form of Cox analysis to this
data set to understand which species best predicted survival and then biochemically and structurally
characterized this species. Our results show that, from the antibodies tested, monoclonal antibody
3B5H10 recognizes a species of mHtt in situ that best predicts neuronal death. This epitope is exposed
in certain conformations of monomeric and possibly small oligomeric polyQ species but disappears in
higher-molecular-weight aggregated forms, such as inclusion bodies. Therefore, protein monomers
and possibly small oligomers containing disease-associated polyQ can adopt a conformation recognized
by 3B5H10 that is pathogenic or closely related to a pathogenic species.

RESULTS
Developing new polyglutamine-specific monoclonal antibodies

We reasoned that antibodies might be useful probes to distinguish species of diffuse Htt in situ and
possibly to identify the species most tightly linked to neurodegeneration. We immunized six mice
against a natively prepared GST-tagged N-terminal fragment of Htt containing the first 171 amino acids
and a disease-associated polyQ (Q66) expansion. Among 480 hybridomas, six produced monoclonal
antibodies that preferentially bound mHtt (Supplementary Results, Supplementary Fig. 1). One,
3B5H10, was further characterized. By immunocytochemistry, we observed that 3B5H10 preferentially
labeled neurons transiently expressing disease-associated polyQ expansions in full-length13 or the exon
1 fragment of Htt (Httex1)10 (Fig. 1a). 3B5H10 specifically recognizes the polyQ expansion in Htt, as the
antibody binds a synthetic polyQ (K2Q39K2) peptide as seen by surface-enhanced laser
desorption/ionization (SELDI)-TOF-MS (Supplementary Fig. 2) and recognizes disease-associated polyQ
expansions in other neurodegeneration-causing proteins that otherwise share no homology with each
other or with Htt2 (for example, androgen receptor14, atrophin15 and ataxin-3 (ref. 16) (Fig. 1b,c).

In western blots of cell lysates transfected with fragments of mHtt, 3B5H10 did not recognize
aggregated species that remained in the stack (Fig. 1d). Immunocytochemistry and immunogold
electron microscopy with striatal neurons transfected with mHttex1 revealed that 3B5H10 recognized
diffuse mHtt but not inclusion bodies (Fig. 1e and Supplementary Fig. 3). In contrast, several other Httspecific antibodies recognized both diffuse mHtt and inclusion bodies (MW7, which recognizes the
polyproline region of Htt located immediately C-terminal to the polyQ stretch4, and EM48, which was
raised against the first 256 amino acids of Htt without a polyQ stretch17) or only inclusion bodies
(MW8, which recognizes the AEEPLHRPK epitope near the polyproline region of Htt4) (Fig. 1e).

Figure 1 | The monoclonal antibody 3B5H10 binds low-molecular-weight disease-associated polyQ expansions.
(a) 3B5H10 preferentially labeled striatal neurons transiently expressing disease-associated polyQ expansions in
an exon 1 fragment or full-length Htt. Striatal neurons transfected with Httex1-eGFP (Q17, Q72) or GFPfull-length
Htt(Q17, Q138) (top row; green) were labeled with the antibody 3B5H10 (bottom row; red) and imaged by
confocal microscopy. Scale bars, 10 Mm. (b,c) 3B5H10 recognizes disease-associated polyQ expansions in other
neurodegeneration-causing proteins. In b, HEK293 extracts containing human influenza hemagglutinin (HA)
epitopetagged androgen receptor (AR) (wild type = Q25, mutant = Q65)14 or GST-tagged atrophin fragments (wild
type = Q19, mutant = Q81)15 were blotted with 3B5H10 and HA- or GST-specific antibodies, respectively. 3B5H10
preferentially recognized versions with disease-associated polyQ expansions. In c, striatal neurons transfected

with Myc-ataxin-3 (wild type = Q27, mutant = Q78)16 were labeled with Myc-specific polyclonal and 3B5H10
antibodies and imaged by confocal microscopy. The Myc-specific antibody (green) recognizes both wild-type and
mutant ataxin-3, whereas 3B5H10 (red) preferentially labels mutant ataxin-3. Scale bars, 5 Mm. (d,e) 3B5H10
recognizes visibly nonaggregated, diffuse forms of mHtt. In d, protein extracts from HEK293 cells expressing Flag
epitope-tagged mHtt (171- Q68-Flag) were blotted with Flag-specific antibody or 3B5H10. Aggregated forms of
mHtt that are retained in the stacking portion of the gel (as in the Flag-specific lane) selectively lose 3B5H10
immunoreactivity. (e) Striatal neurons transfected with Httex1-( Q46, Q72 or Q97)-eGFP were labeled with Alexa
647-conjugated 3B5H10 and MW8, MW7 or EM48 Htt-specific antibodies. Fluorescence from GFP (green), Alexa
647 (blue) and Cy3-conjugated secondary antibodies (red) to detect MW8, MW7 or EM48 was collected with
confocal microscopy. Scale bars, 10 Mm.

Figure 2 | Quantitative binding of Htt-specific antibodies 3B5H10, EM48, MW1 or MW7 to Httex1 is
distinguishable and predictable. (a) 3B5H10, EM48, MW1 and MW7 differ considerably in their quantitative
binding to diffuse Htt in situ, suggesting that each recognizes a unique Htt species. Quantitative binding for each
of the antibodies to Httex1 can be estimated by regression analysis when the fluorescence of the eGFP tag fused
to Httex1 and the polyQ length of Httex1 are known. Striatal neurons transfected with Httex1-( Q17, Q46, Q72 or
Q97)-eGFP were fixed at 24 h and subjected to immunocytochemistry with one of the four Htt-specific
antibodies. Fluorescence was measured by confocal microscopy (1748 neurons per condition). For this analysis,
only neurons without inclusion bodies were measured. a.u., arbitrary units. (b) The appreciable data scatter
around the linear regression lines in a suggested that predicting the amount of antibody binding to a given mHtttransfected neuron carries nontrivial estimation error. To account for this error, we reanalyzed the data in a with
Bayesian statistics. The output of Bayesian regression analysis is a probability plot demonstrating how likely the
actual regression coefficient (α) is a particular value. Bayesian regression plots for 3B5H10 are presented here,
and A values for the other antibodies are presented in Supplementary Figure 5.

In brain tissue sections from Huntingtons disease model mice, we confirmed that 3B5H10 recognizes
diffuse mHtt over inclusion bodies (Supplementary Fig. 4). In 12-month-old BACHD mice, a Huntingtons
disease model expressing full-length mHtt (Q97)18, aggregates are relatively abundant, but 3B5H10
primarily stains diffuse mHtt. When aggressive antigen retrieval involving formic acid was used,
3B5H10 staining of BACHD tissue revealed more prominent staining of neuropil aggregates (data not
shown). In 15-week-old R6/2 mice, a Huntingtons disease model expressing an N-terminal fragment of
mHtt (~Q150)19, essentially all mHtt is aggregated into inclusion bodies, and 3B5H10 staining is poor.
However, after R6/2 brain tissue is treated with 90% formic acid, 3B5H10 staining (primarily of
inclusion bodies) increases. 3B5H10 staining after these aggressive antigen retrievals is most likely
attributable to the unmasking of polyQ epitopes not normally exposed in vivo.
We also confirmed that 3B5H10 recognizes full-length mutant ataxin-3 in another animal model of
polyQ neurodegeneration, the YAC-SCA3 mouse20 (Supplementary Fig. 4). Together, our results suggest
that select antibodies can distinguish among different species of polyQ protein in situ7.

Decoding pathogenic significance of Htt species in situ

We next sought to understand the pathogenic significance of epitopes recognized by 3B5H10 and
other Htt-specific antibodies. To do so, we turned to multivariate Cox analysis. Cox analysis is one of
the most widely used survival models in clinical research for discovering and measuring factors that
predict an outcome of interest8,9. The technique allows one to quantitatively rank the importance of
numerous risk factors present at the same time with respect to an outcome of interest.
Applying multivariate survival analysis to the question of which mHtt epitope (simultaneously present
risk factors) best predicts neurodegeneration requires an estimation of the amount of each epitope in
individual live neurons and a determination of how long each of those neurons lives. However, to
estimate the amount of each epitope in individual live neurons, we were faced with the conundrum
that antibody staining requires fixation. Thus, though we could measure a given neurons epitope
levels, we could not then directly analyze its survival time.
To overcome this problem, we first measured how the abundance of different Htt epitopes in striatal
neurons recognized by these antibodies varied with incremental changes in Htt expression and polyQ
length in situ. We transfected striatal neurons with Httex1 fused to enhanced green fluorescent protein
(eGFP) containing Q17, Q46, Q72 or Q97 (Httex1-Qn-eGFP), fixed the neurons and then compared the
monoclonal antibodies 3B5H10, MW7, EM48 and MW1 (ref. 4) through immunostaining experiments.
Similar to 3B5H10, MW1 preferentially binds diffuse mHtt; however, it evidently binds to an extended,
unfolded polyQ stretch21, whereas 3B5H10 binds to a compact structure of polyQ (unpublished
observations). We found that the four antibodies differed considerably from each other in their
quantitative binding to diffuse Htt in situ (Fig. 2a). Particularly notable was the fact that 3B5H10 and
MW1, despite both preferentially recognizing expanded polyQ stretches, show distinct quantitative
binding profiles, which suggest that they distinguish different conformational epitopes of polyQ in situ.
More importantly, each one of the antibodies tested had predictable binding, which could be
estimated from the length of the polyQ expansion and the amount of diffuse Htt. Therefore, to
estimate the amount of each epitope in individual live neurons, we can measure a live neurons diffuse
Htt-eGFP levels (via eGFP fluorescence in live fluorescence microscopy) and then mathematically infer
the amount of each epitope in that neuron with data from Figure 2a and regression analysis. Using
regression analysis, however, means that the amount of each epitope estimated for a given neuron
carries an inherent estimation error. To account for this uncertainty in estimation, we applied Bayesian
regression analysis, a technique whose output is a probability plot of regression coefficient values (Fig.
2b and Supplementary Fig. 5).
With the ability to estimate how much of each mHtt epitope exists in a given live neuron, we next
turned to determining how long that neuron lives. Such data allow us to relate multiple,
simultaneously present risk factors (mHtt epitopes) to an outcome of interest (neuronal death) by
multivariate Cox analysis. We again transfected striatal neurons with Httex1 fused to eGFP and Q17, Q46,
Q72 or Q97, and we performed longitudinal survival analysis. Beginning approximately 24 h after
transfection, thousands of those neurons were tracked individually and daily for 710 d with an
automated microscope. The amount of diffuse Htt in individual neurons that did not form inclusion
bodies during the total experimental time was quantified by measuring eGFP intensity10.
Simultaneously, we determined how long each neuron lived. Thus, using Bayesian regression analysis

(Fig. 2b), we were able to assemble a data set that contained the Htt epitope levels and survival times
for thousands of individual neurons (Fig. 3).
However, to employ multivariate Cox analysis on this dataset, we had to account for the inherent
uncertainty in epitope values, which derived from having to estimate these values by regression
techniques. We addressed this estimation error issue with a well-established method called
hierarchical Bayesian analysis22,23. Details of this hierarchical model are presented in Supplementary
Methods and are depicted in Figure 3 and Supplementary Figure 6. In comparing the prognostic values
of epitopes recognized by 3B5H10, MW1, EM48 and MW7, we discovered that only the 3B5H10
epitope significantly predicts (Bayesian probability > 98.9%) whether and when neurodegeneration will
occur (Fig. 4 and Table 1).

Figure 3 | New methodology distinguishes which of several simultaneously existing in situ epitopes of diffuse
Httex1 best predicts neurotoxicity. (a) The survival of individual neurons and the amounts of diffuse Httex1-( Q17,
Q46, Q72 or Q97)-eGFP they contained were determined by automated microscopy and recorded in a spreadsheet.
Next, we used the regression coefficients from Figure 2 to relate diffuse Httex1-Qn-eGFP levels to antibodybinding values (bottom; copied from Fig. 2a). To account for the inaccuracy inherent in estimating antibodybinding values from the graphs at bottom, we technically calculated regression coefficients using Bayesian
methods (Fig. 2b and Supplementary Fig. 5). Scale bar, 25 Mm. (b) Using the regression coefficients from the
plots in Figure 2, we can estimate how much antibody staining would have occurred in each neuron. These
antibody staining values are then noted in the spreadsheet. (c) Finally, using the estimated amount of antibody
staining and survival time of each neuron, we compared the epitopes with each other using Bayesian
hierarchical survival (Cox) analysis, which determines the antibody that best predicts degeneration. Hierarchical
Bayesian methods ensure that estimation errors from each step of the analysis propagate through to the final
readout. A more detailed schematic of our approach is illustrated in Supplementary Figure 6 and is detailed in
Supplementary Methods. a.u., arbitrary units.

We were surprised that our analysis demonstrated that 3B5H10 is a better predictor of
neurodegeneration than MW1, given that the binding of both antibodies is grossly correlated to the
length of the polyQ expansion. However, closer inspection of the increase in binding of each antibody
with longer polyQ stretches reveals differences in the rate of increase between 3B5H10 and MW1 (Fig.
2a). Picking up on these differences, survival analysis allows us to conclude that the pattern of increase
in the case of 3B5H10 more closely predicts the corresponding changes in risk of death than the
pattern for MW1. To investigate further the ability of the system to resolve subtle differences in the
prognostic power of antibodies that recognize polyQ expansions, we evaluated the commonly used
monoclonal antibody 1C2, which was raised against the polyQ-containing transcription factor TBP. We

found that the relationship of 1C2 binding to Htt expression was intermediate between MW1 and
3B5H10 (Supplementary Fig. 7). However, the differences in the binding patterns between 3B5H10 and
1C2 were smaller than those between 3B5H10 and MW1: small enough, in fact, to exceed the
sensitivity limits of survival analysis. In general, when differences between two risk factors in a survival
model fall below a certain threshold, the survival analysis ceases to have reliable biological meaning.

3B5H10 binds a very small species of Htt

Given the prognostic value of the 3B5H10 epitope, we sought to characterize this epitope further.
Although 3B5H10 does not recognize inclusion bodies (Fig. 1), we considered whether 3B5H10 might
bind oligomers or other aggregation intermediates in the diffuse Htt fraction of neurons, as these
species have been proposed to be toxic in Huntingtons, Parkinsons and Alzheimers diseases24,25. To
search for oligomers in live neurons in the diffuse fraction of mHtt, we measured concentrationcorrected Förster resonance energy transfer (N-FRET)26 between Htt fragments. Primary cortical
neurons transfected with Httex1 fragments containing wild-type (Q25) or expanded (Q97) polyQ stretches
and tagged with cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP) (Httex1- Q25-CFP,
Httex1- Q25-YFP, Httex1- Q97-CFP, Httex1- Q97-YFP) were imaged27. Although we detected significant (P <
0.0001) FRET from mHtt within inclusion bodies (Fig. 5a), the amount of FRET in regions of neurons
containing diffuse Htt were low and were similar regardless of whether that neuron contained mutant
or wild-type Htt.

Figure 4 | A species of Htt recognized by 3B5H10 best predicts striatal neurodegeneration. The significance to
neurodegeneration of Htt species formed in situ and distinguished by 3B5H10, MW1, MW7 or EM48 was
assessed by Cox analysis with a hierarchical Bayesian statistical approach (Fig. 3). Each graph plots the Cox
coefficient (B) value for a particular antibody on the x axis and the probability of that coefficient value on the y
axis. A positive coefficient signifies that antibody staining is associated with decreased survival. A negative
coefficient signifies improved survival. (a) Cox coefficient (B) distribution for 3B5H10, (b) MW1, (c) MW7 and (d)
EM48.

Table 1 | Mean of the probability distributions for each antibodys Cox coefficient
Antibody Mean (Coef) P (Coef < 0)
3B5H10
0.169
0.0109
MW1
–0.0216
0.704
MW7
0.0157
0.302
EM48
–0.0404
0.713
Cox coefficients (Coef, β) are from Figure 4. A positive Cox coefficient predicts decreased survival, and a
negative Cox coefficient predicts increased survival. Of the four antibodies, 3B5H10 bound a species of Httex1
that predicted degeneration the best (mean probability, P, of 3B5H10’s Cox coefficient is positive; that is,

approximately 99% of the area under the curve is above 0). Cox coefficients associated with the other antibodies
tested had probability distributions centered around zero.

As a FRET signal from oligomeric association of mHtt in the SH-SY5Y cell line has been previously
reported with monomeric versions of CFP and YFP (mCFP or mYFP) attached to Httex1 (ref. 25), we
transfected striatal neurons with these previously reported constructs (Httex1- Q17-mCFP, Httex1- Q17mYFP, Httex1- Q58-mCFP, Httex1- Q58-mYFP) but again found that the amount of FRET in regions of
neurons containing diffuse mHtt were low and not significantly different (P = 0.365) from those of wildtype Htt (Supplementary Fig. 8a). In a final attempt to increase the sensitivity of our FRET assay, we
transfected striatal neurons with wild-type (Q17) and mutant (Q46) Httex1 constructs C-terminally tagged
with CyPet or YPet, a pair of fluorophores evolutionarily optimized for improved sensitivity over
traditional FRET pairs such as CFP and YFP28. Once again, the FRET signals from the diffuse fraction of
neurons transfected with mutant and wild-type Htt were indistinguishable (P = 0.449) (Supplementary
Fig. 8b).
As we were unable to obtain a FRET signal in the diffuse fraction of mHtt-transfected live neurons, we
attempted to detect oligomeric intermediates in the diffuse fraction through immunocytochemical
staining with an oligomer-specific antibody that recognizes polyQ protofibrillar oligomers3. Whereas in
vitro aggregation of Httex1- Q53 (ref. 29) led to oligomer-specific antibody staining on a dot blot, the
antibody failed to label diffuse mHtt in striatal neurons by immunocytochemistry despite labeling and
fixation conditions that were highly analogous to those of our dot-blot procedure (Supplementary
Methods and data not shown). Thus, we were unable to experimentally demonstrate the presence of
aggregated species in the diffuse mHtt fraction of neurons in situ.
Despite our failure to detect oligomeric species in the diffuse mHtt fraction of neurons, 3B5H10 might
still be more sensitive at detecting Htt aggregation intermediates than FRET or the oligomer-specific
antibody. To test this possibility in vitro, we performed a filter retardation assay with extracts from
HEK293 cells transfected with N-terminal 171-amino-acid fragments of Htt containing different polyQ
stretches (Q17, Q40, Q68, Q89, Q142) and a C-terminal Flag epitope (Htt-171-Qn-FLAG)30. FLAG blotting
revealed that aggregation intermediates were formed and retained on the membrane (>0.20 Mm);
however, 3B5H10 failed to detect these aggregates (Fig. 5b).

Figure 5 | 3B5H10 does not recognize large oligomers of mHtt. (a) N-FRET (mean o s.d.) from cortical neurons
was high in inclusion bodies (IBs) formed from Httex1- Q97-CFP and Httex1- Q97-YFP (Q97 IBs) but low in regions of
neurons with diffuse mHtt (Q97 diffuse) and not significantly different than in neurons with Httex1- Q25-CFP and
Httex1- Q25-YFP (Q25) (P = 0.15) or CFP and YFP (FP only) (P = 0.22). Scale bars, 10 Mm. NS, not significant. (b)
HEK293 extracts containing Htt-171-( Q17, Q40, Q68, Q89 or Q142)-Flag were loaded on a 0.20-Mm membrane slot
blot and probed with Flag-specific antibody or 3B5H10. The Flag-specific antibody revealed submicroscopic
aggregates of Htt-171-(Qn)-Flag that were unrecognizable by 3B5H10. (c) Agarose gel electrophoresis of extracts
from PC12 cells stably expressing truncated (no polyproline) Httex1-Q103-GFP were blotted with GFP-specific
antibody or 3B5H10. Whereas oligomeric Httex1-Q103-GFP was present (arrow), 3B5H10 only stained the dye
front, which represents monomer and possibly small oligomers. (d) 3B5H10 prevents mHtt aggregation detected
by AFM. Httex1-Q53 aggregation was triggered with or without 3B5H10. (e) AFM-detectable species observed with
3B5H10 alone or with 3B5H10 or MW8 added to monomeric Httex1- Q53. 3B5H10 addition to Htt stabilizes a 2- to
3-nm globular species, consistent with the size of a monomeric Htt-antibody complex. (f) AFM-detectable
species observed with 3B5H10, MW8, buffer or nothing added to preaggregated (preagg) oligomers of Httex1Q53. 3B5H10 had similar effects when added to preformed fibrils (Supplementary Fig. 10). (g) The final size of
AFM-detectable species when 3B5H10 is added to monomeric Httex1- Q53 (as in e) or preaggregated oligomers
(as in f) is statistically indistinguishable (Spearmans rank correlation coefficient; P < 0.0001 for the null
hypothesis stating that sizes are different). This size is most consistent with a monomeric Htt-antibody complex.

Figure 6 | Epitope recognized by 3B5H10 is preferentially present in low-molecular-weight Htt species. (a) A
solution of Httex1- Q53 was chemically crosslinked and probed with MW7 or 3B5H10. MW7 staining confirms the
presence of monomers and small oligomers. The epitope 3B5H10 recognizes is preferentially present in
monomers over small oligomers (full blot is in Supplementary Fig. 11). (b) Monovalent 3B5H10 Fab retains
specificity for mHtt over wild-type Htt, similar to intact bivalent 3B5H10. 3B5H10 Fab was cleaved from the
intact IgG by papain proteolysis and purified by ion-exchange and size-exclusion chromatography. HEK293
extracts containing Htt-171-( Q17 or Q68)-Flag were combined and blotted with vehicle, chromatographic
fractions corresponding to purified Fab or intact 3B5H10 IgG, or undigested 3B5H10. This was followed by
secondary antibody incubation with Flag-, Fc- (which recognizes only intact antibodies) or Fab-specific (which
recognizes Fabs or intact antibodies) antibodies. (c) Purified 3B5H10 Fab and thio- Httex1-Q39-His6 were combined
at different molar ratios (Fab/Htt = 0.25, 0.5, 1, 1.5, 2) and analyzed by size-exclusion chromatography. A single
peak consistent with a 1:1 Fab-Htt complex was observed: peaks of pure 3B5H10 Fab or thio- Httex1-Q39-His6
appeared if either was in molar excess of the other. (d) Purified 3B5H10 Fab and thio- Httex1- Q39-His6 were
combined and analyzed by equilibrium sedimentation analytical ultracentrifugation. The data best fit a model in
which 3B5H10 Fab binds Httex1 in a 1:1 ratio. At high concentrations, the complex dimerizes. Predictions for this
model are overlaid on the raw data curves. The even distribution of residuals suggests no bias in the fit.

We were concerned that the SDS concentrations used in our filter retardation assay may disrupt the
stability of some Htt oligomers, so we turned to agarose gel electrophoresis, which uses a lower SDS

concentration, no reducing agent and no heating of the sample before gel loading. Using extracts from
a PC12 cell line stably expressing a fragment of mHtt tagged to GFP (Q103)31, we detected a range of
oligomers with a GFP-specific antibody. However, 3B5H10 failed to recognize these oligomers, binding
only to the leading edge of the agarose gel (Fig. 5c). Thus, 3B5H10 appears to bind only a monomeric
or small oligomeric species of mHtt, even in the presence of larger oligomeric species.
To investigate whether 3B5H10 binds to smaller oligomeric structures, we used atomic force
microscopy (AFM) and GST Httex1- Q53 (ref. 29). We reasoned that the presence of 3B5H10 upon GST
cleavage and subsequent Httex1- Q53 aggregation might stabilize the species that it binds and arrest the
production of more aggregated species. 3B5H10 addition almost completely prevented the expected
time-dependent increase in oligomer and fibril formation by Httex1- Q53 (Fig. 5d). Confirming our AFM
studies, dynamic light scattering performed on a solution of purified Httex1 with an N-terminal
thioredoxin tag and a C-terminal hexahistidine tag (thio- Httex1- Q39-His6) showed that 3B5H10 addition
inhibited aggregation and kept particle size small and stable for up to a month (Supplementary Fig. 9).
AFM measurements of the height (nm) of the mHtt species formed in the presence of 3B5H10 revealed
that these globular structures were most consistent with complexes of a single antibody and single
mHtt molecule. The structures were larger than those in samples of 3B5H10 alone but significantly (P >
0.26 for the null hypothesis stating that sizes are different) smaller than structures that emerged when
Httex1- Q53 was incubated with MW8, an antibody that recognizes aggregated forms of mHtt (Fig. 5e)7.
Remarkably, we also found that the addition of 3B5H10 to pre-formed oligomeric structures led to
their disaggregation, as monitored by AFM (Fig. 5f). In contrast, preformed oligomers persisted after
the addition of buffer or MW8. When the 3B5H10 dissolution process was allowed to proceed to
completion, 3B5H10 dissolved preformed oligomers into AFM-detectable species that had the
dimensions of a monomer of mHtt complexed to 3B5H10 (Fig. 5g). Thus, even when oligomers are
present, 3B5H10 seems incapable of stably binding these structures. Notably, no SDS was used in these
experiments, so oligomeric species that would have been unstable in the minimal SDS of agarose gel
electrophoresis experiments (Fig. 5c) were presumably available for 3B5H10 binding. We also
discovered that 3B5H10 not only dissolves oligomers but also preformed fibrils in a dose- and timedependent manner (Supplementary Fig. 10). In contrast, 3B5H10 had no effect on fibrils formed by a
different amyloidgenic protein, A-synuclein. Nor did MW8 disrupt mHtt fibrils (data not shown).
Notably, the final size of preformed fibrils dissolved by 3B5H10 is the same as structures formed when
3B5H10 is added to monomeric mHtt, a size most consistent with a complex of monomeric mHtt and
antibody7.

3B5H10 preferentially recognizes monomers of mHtt

Though our results suggested that 3B5H10 preferentially recognizes a very small species of mHtt, we
sought more definitive experimental validation by crosslinking experiments, size-exclusion
chromatography and sedimentation equilibrium analytical ultracentrifugation. Because 3B5H10s ability
to slowly dissociate Htt oligomers could confound our analysis of the species it binds, we tested its
ability to bind monomers and small oligomers of Htt prestabilized via chemical crosslinking. Blotting of
crosslinked Htt by MW7 revealed the presence of monomers and small oligomeric species; however,
the epitope that 3B5H10 recognizes is preferentially present in monomers, although a lesser amount of
it may also be present in small oligomers (Fig. 6a).

To further characterize the species 3B5H10 binds to, we turned to size-exclusion chromatography.
Because 3B5H10 IgG is bivalent and could potentially bind two epitopes or antigen molecules
simultaneously in size-exclusion chromatography32, we first purified monovalent Fabs (mass = 47.65
kDa) from 3B5H10 (ref. 13). Importantly, western blot analysis on HEK293 cell extracts containing Htt171-( Q17 or Q68)-Flag proteins showed that, like the intact antibody, 3B5H10 Fab retained a strong
binding preference for mHtt (Fig. 6b). We then mixed 3B5H10 Fab and pure thio- Httex1- Q39-His6 (27.10
kDa)33 at different molar ratios (Fab/mHtt; 0.25, 0.5, 1, 1.5, 2) and separated the constituents by sizeexclusion chromatography. The 1:1 mixtures contained a peak whose elution time was consistent with
the expected molecular mass of a complex between Fab and mHtt (74.75 kDa). Higher or lower ratios
led to the appearance of an additional peak corresponding to unbound Fab or mHtt (Fig. 6c),
suggesting that 3B5H10 Fab preferentially binds monomeric mHtt in a complex with a 1:1
stoichiometry.
To confirm these results, we analyzed the mass and stoichiometry of the 3B5H10 FabmHtt complex by
sedimentation equilibrium analytical ultracentrifugation, a method that determines molecular mass
independently of shape. The best fit for data acquired at three FabmHtt concentrations and four rotor
speeds was a model in which 3B5H10 Fab and thio- Httex1- Q39-His6 form a stable monomeric 1:1
complex that dimerizes at higher concentrations (>0.05 mg ml1) (Fig. 6d). Monte Carlo analysis
revealed a dimerization Kd of 340 nM (95% confidence interval, 240490 nM). The molecular mass
predicted for the 1:1 complex was 73.4 kDa, which is 98.1% of its calculated mass (74.75 kDa, not
shown). Notably, a model in which the Fab binds a dimer of mHtt was tested and explicitly rejected
(Supplementary Fig. 12). Supporting these results, small-angle X-ray scattering also indicates that
3B5H10 Fab preferentially binds mHtt in a 1:1 ratio (unpublished data). We therefore conclude that
3B5H10, which binds an epitope of mHtt that is an especially strong predictor of neuronal death,
preferentially recognizes monomers (and possibly very small oligomers) of mHtt and that the preferred
stoichiometry for the binding of the 3B5H10 Fab to mHtt is 1:1.

DISCUSSION

In this study, we developed new methods to understand which of several simultaneously existing in
situ epitopes of diffuse mHtt best predicts neurotoxicity. We used a series of antibodies to distinguish
species of Htt in situ and then used automated microscopy with survival analysis to determine whether
any of them predicted toxicity in a primary striatal neuron model of Huntingtons disease. Among the
four antibodies we compared (3B5H10, MW1, MW7 and EM48), the newly developed monoclonal
antibody 3B5H10 bound a species of Htt that best predicted neurodegeneration.
The epitope recognized by 3B5H10 is contained within the polyQ stretch of mHtt but disappears as
mHtt aggregates into inclusion bodies. The epitope exists in both full-length and exon 1 fragments of
mHtt but is negligibly present in wild-type Htt. Further, the epitope also exists in mutant forms of other
polyQ-containing proteins that cause neurodegeneration, including the androgen receptor, atrophin
and ataxin-3. Finally, we determined that the epitope exists in certain conformational folds of polyQ
associated with low-molecular-weight Htt species (monomers and possibly very small oligomers).
We considered whether 3B5H10 is capable of binding oligomers of mHtt even though it preferentially
binds a monomeric species. Though 3B5H10 strongly stains the diffuse mHtt fraction of neurons, we

did not detect oligomers in this fraction by FRET or an oligomer-specific antibody. Slot blotting, agarose
gel electrophoresis, AFM and dynamic light scattering (Fig. 5 and Supplementary Figs. 9,10) confirmed
that the epitope recognized by 3B5H10 is present in a very low-molecular-weight species of Htt (likely
monomer and possibly small oligomer). Chemical crosslinking experiments (Fig. 6a) confirmed that the
epitope 3B5H10 recognizes is present in monomers and, to a lesser degree, in very small oligomers of
Htt. 3B5H10s tendency to bind monomers over oligomers was further supported by results from sizeexclusion chromatography (Fig. 6c), sedimentation equilibrium analytical ultracentrifugation (Fig. 6d)
and small-angle X-ray scattering (unpublished observations).
A recent study on the formation of different conformations of mHtt found that 3B5H10 may bind a
conformation of amyloid formed in vitro at 4 C (ref. 34). This structure, unlike that of amyloid formed
in vitro at 37°C, has a loop-turn organization that exposes loose hairpins of polyQs. Additionally, certain
biochemical purification techniques may facilitate de novo exposure of the 3B5H10 epitope on
oligomers35, a process analogous to the unmasking of the 3B5H10 epitope upon aggressive antigen
retrieval of animal model brains affected with Huntingtons disease (Supplementary Fig. 4). Combining
these observations with our data showing very faint 3B5H10 staining of crosslinked small Htt oligomers
(Fig. 6a), we conclude that with certain in vitro conditions or specific biochemical and
immunohistochemical methods, the conformation of polyQ recognized by 3B5H10 may appear in
aggregated species of Htt.
The ability of 3B5H10 to dissociate preformed oligomers and fibrils into monomeric Htt (Fig. 5f,g and
Supplementary Fig. 10) was surprising. We are aware of only one other Htt-specific antibody that
demonstrates this property, MW7 (ref. 7). However, MW7 appears to dissolve preformed fibrils into
AFM-detectable species with dimensions that are consistent with an oligomer rather than a monomer.
We speculate that 3B5H10 may promote oligomer and fibril dissociation by sequestering monomers
that could be dynamically associating and dissociating with oligomers or fibril ends36,37.
As 3B5H10 and MW1 both bind polyQ expansions in a length-dependent manner and preferentially
recognize diffuse mHtt in situ4,33, it is surprising that only 3B5H10 binding predicts neurodegeneration
by multivariate Cox analysis (details in legend for Supplementary Fig. 5). One explanation is that MW1
and 3B5H10 bind mostly distinct conformers of mHtt, only one of which may have prognostic value.
Previous studies demonstrated that MW1 recognizes expanded polyQ as a linear lattice21,33. In such a
model, the antibody binds weakly to a relatively unstructured epitope of wild-type polyQ. As the length
of the polyQ stretch approaches that associated with disease, the unstructured epitope repeats.
Because antibodies are bivalent, the presence of two epitopes in tandem results in dramatically
increased binding by MW1 owing to increased avidity (Supplementary Fig. 13). In contrast, our results
and our unpublished structural data demonstrate that 3B5H10 recognizes a compact, structured
epitope of polyQ that is minimally present in wild-type Htt and is exposed or created in mHtt. Thus,
rather than preferentially binding expanded polyQ via increased avidity, 3B5H10 shows a strong affinity
for mutant polyQ. Supporting these conclusions, MW1 Fab forms a 3:1 complex33 with the exact
version of Htt (thio- Httex1- Q39-His6) that we found forms a 1:1 complex with 3B5H10 Fab (Fig. 6c,d and
Supplementary Fig. 13). Thus, the linear lattice epitope that MW1 recognizes is no larger than 13
glutamines, consistent with crystallographic studies of MW1 complexed with a polyQ peptide21. Also
supporting these conclusions, the Fab of MW1, which is monovalent and therefore cannot bind its

target through an avidity mechanism, loses most of its preference for mutant over wild-type polyQ33.
In contrast, the Fab of 3B5H10 retains a preference for mutant polyQ (Fig. 6b and Supplementary Fig.
13). These observations, combined with our structural studies (unpublished data), suggest that lowmolecular-weight species of mHtt may exist in more than one conformation and that the one
recognized by 3B5H10 might be toxic or closely related to a toxic species (Fig. 7)38-40.

Figure 7 | The linear lattice versus emergent conformation hypotheses for expanded polyQ conformation. The
linear lattice model posits that a relatively unstructured epitope of polyQ in wild-type (Wt) Htt repeats itself as
the polyQ stretch expands. The emergent conformation model posits that expansion of the polyQ stretch
induces a conformational change, such that wild-type and mutant polyQ are in distinct conformations. As shown
in the middle panel, the linear lattice and emergent conformation hypotheses are not mutually exclusive; both
models may be simultaneously true for mHtt. Alternatively, some mHtt molecules may show linear lattice
epitope repeats, whereas others may have an emergent conformation, possibly in the same neuron. Assessment
of prognostic value for both epitopes by Cox analysis reveals that the emergent conformation, recognized by
3B5H10, is more toxic or more closely related to a toxic species than the linear lattice epitope, recognized by
MW1.

A burgeoning body of work in polyQ disease research suggests that culprit proteins may exert their
toxic gain of function by enhanced native activity (especially via native protein-protein
interactions41,42). As our exon 1 model of Huntingtons disease, by definition, does not encompass all
native function of full-length Htt, with our approach we may miss pathogenic events that rely on the
native activity of Htt outside exon 1. Though technical barriers prohibited us from designing a fulllength primary culture model of Huntingtons disease for these experiments, we have previously
extensively validated our exon 1 model as a faithful model of the disease43. Further, we demonstrate in
this paper the ability of 3B5H10 to recognize full-length mHtt, ataxin-3 and androgen receptor, thereby
establishing the presence of the predictive epitope in full-length protein. Finally, we note that the
majority of known Htt interactors bind to the N terminus of Htt44-46, and in some cases the binding
region has been defined even more narrowly to exon 1 (ref. 46). Thus, we favor the hypothesis that the
3B5H10 conformer of Httex1 still mediates toxicity at least partially through native activity, including
enhanced interactions with some exon 1 interactors and diminished interactions with others.
We previously found that inclusion body formation is associated with improved neuronal survival10,
and in our current studies we discovered that inclusion body formation leads to a substantial loss of
intraneuronal 3B5H10 binding. In contrast, it does not lead to a loss of EM48 or MW7 binding (Fig. 1e).
As 3B5H10 binds a species of mHtt that strongly predicts death (better than the epitopes recognized by
EM48 or MW7, for example), inclusion body formation might confer protection by preferentially
reducing, masking or refolding the 3B5H10 epitope (Supplementary Fig. 14)47.
The new methodology we used may be broadly applicable to the study of diseases associated with
protein malfolding. Elucidating toxic species of aggregation-prone proteins is difficult because these

species may be rare, their existence may depend on endogenous protein interactions that defy
biochemical purification and the tools to study protein conformation in situ are limited. We showed
that combining the use of conformation-specific antibodies and automated imaging with longitudinal
analysis provides a way to probe protein conformation in situ and elucidate the prognostic significance
of one conformer in the context of others. We expect that the better a conformer predicts
neurodegeneration, the more tightly it is linked to toxicity and pathogenesis.

METHODS

Antibodies and plasmids. Production of new Htt-specific monoclonal antibodies and creation of new
constructs are described in Supplementary Methods.
Cell culture, transfection, automated microscopy and image analysis. Cell culture, transfection,
automated microscopy and image analysis were performed as described10,12,13,48,49 and are detailed
further in Supplementary Methods.
Immunocytochemistry, immunohistochemistry, confocal microscopy and electron microscopy.
Immunochemical techniques and subsequent confocal and electron microscopy imaging and
quantification are described in Supplementary Methods.
3B5H10 binding to polyQ peptide. PolyQ (K2Q39K2) or PACAP peptide (basic peptide) was spotted on a
PS10 ProteinChip Array (Bio-Rad) and loaded into a ProteinChip SELDI System (Bio-Rad) for data
collection. Details on how the peptide was spotted are available in Supplementary Methods.
Hierarchical Bayesian statistical analysis of predictive power for various Htt-specific antibodies. The
statistical model we used to determine how well epitopes recognized by each antibody predict
neurotoxicity are outlined in Figure 3 and Supplementary Figure 6. The mathematical explanation of
our model is available in Supplementary Methods.
Concentration-corrected Förster resonance energy transfer (N-FRET). N-FRET was performed as
described26 and is further detailed in Supplementary Methods.
Dot blots for oligomer-specific staining of Htt. Modifications to traditional dot blotting for detection of
oligomer-specific staining of Htt are detailed in Supplementary Methods.
Filter retardation assay. Lysate was centrifuged at 20,000g at 4 C, and the pellet was resuspended in
20 mM Tris-HCl (pH 8.0), 15 mM MgCl2 and incubated at 37°C for 1 h. A sample from this insoluble
material was diluted in 2% SDS and loaded on a cellulose acetate membrane (AcetatePlus, pore size
0.22 Mm; Osmonics) previously rinsed three times with 2% SDS using a slot-blot apparatus (PR 648
slot-blot manifold, GE Healthcare). After loading the samples, wells were washed again three times
with 0.1% SDS, and the membrane was blotted. More details are available in Supplementary Methods.
Agarose gel electrophoresis of PC12 lysates. Conditions for detecting oligomers of mHtt from PC12
lysates in semi-native form are described in Supplementary Methods.
Atomic force microscopy. AFM experiments were performed using a MFP-3D scanning probe
microscope (Asylum Research). Detailed settings and sample preparation are described in
Supplementary Methods.

Chemical crosslinking. Cleavage and aggregation of GST- Httex1- Q53, crosslinking with glutaraldehyde
and immunoblotting with MW7 or 3B5H10 are described in Supplementary Methods.
Size-exclusion chromatography. Experiments were carried out under a constant Htt concentration (0.2
mg ml-1), with adjustment of the Fab concentration to achieve Fab/Htt ratios of 1:4, 1:2, 1:1, 1.5:1 and
2:1. Total volume for each sample loaded on the size-exclusion column was 500 Ml.
Analytical ultracentrifugation. Samples of 3B5H10 Fab and thio- Httex1- Q39-His6 (1:1 molar ratio) in 10
mM Tris-HCl pH 8.0 and 50 mM NaCl were analyzed with a Beckman Coulter XL-A Ultima analytical
ultracentrifuge using a Ti60 rotor and cells with six-channel centerpieces. Experiments were carried out
at three different total protein concentrations (0.53 mg ml1, 0.80 mg ml-1 and 1.07 mg ml-1). Samples
were run at four different rotor speeds (10,000 r.p.m., 15,000 r.p.m., 20,000 r.p.m. and 25,000 r.p.m.)
at 20°C for 1631 h (at each speed) to achieve sedimentation equilibrium, which was confirmed by
overlapping scans taken 2 h apart. Analysis of analytical ultracentrifugation data is described in
Supplementary Methods.
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